of reversible forms of hypertensive vascular disease. Unfortunately, altogether these entities account for only a small fraction of patients with hypertension.
The pathogenesis and management of essential hypertension remain the first priority of a national program to reduce disability and death from cardiovascular disease. If past experience is a guide, it is almost a certainty that studies of patients with so-called "essential" hypertension will lead to the recognition of other specific hypertensive syndromes, which can then be separated for the application of specific corrective therapy.
Recent studies of patients with malignant hypertension have made inroads to this large problem. It was found that patients with malignant hypertension practically always exhibited marked oversecretion of the sodiumretaining hormone aldosterone.1 Because of the consistent presence of renal damage in this syndrome, these observations led to studies which demonstrated in normal subjects that aldosterone secretion is specifically activated and controlled by the pressor hormone of renal origin, angiotensin 11. 2 The studies pointed to the existence of a renal-adrenal hormonal system for the normal regulation of sodium balance, a derangement of which appears to be critically involved in the pathogenesis of malignant hypertension.3
In the operation of this hormonal system, renin is secreted into the bloodstream whenever the perfusion of the kidney is compromised by a fall in arterial blood pressure. This may be induced by a variety of stimuli that might contract blood volume, such as hemorrhage or sodium depletion. Renin acts enzymically on a plasma globulin to release angiotensin II. Angiotensin II, in addition to being the most powerful pressor substance known, elicits increased aldosterone secretion. Normally, the pressor and sodium-retaining effects of angiotensin and aldosterone operate together to restore blood volume and renal perfusion and shut off the initial signal for renal renin release.
In malignant hypertension, because of a critical degree of renal damage, inappropriate excesses of the enzyme renin are released into the circulation and this stimulates aldosterone secretion. The normal feedback loop, which ordinarily would react to the coexistence of excessive amounts of angiotensin and aldosterone in the blood, cannot be closed because the damaged target organ, the kidney, is unresponsive. A vicious cycle develops involving a self-sustaining pattern of more renal damage, more hypertension and vascular damage, and more hypersecretion of renin. The derangement probably accounts for' the diffuse vascular damage and accelerated course of the disease. 3 That renin is a vasculotoxic agent is also supported by animal experiments. Thus, malignant but not benign experimental Goldblatt's hypertension is associated with excesses of renin and aldosterone,4 and fatal vasculitis is produced by the simultaneous administration of renin and aldosterone in rats. 5 It is also possible to explain the benign nature of the hypertensive disease associated with primary aldosteronism in the context of this renal-adrenal hormonal interaction. In this condition, oversecretion of aldosterone, arising from an autonomous adrenal-cortical adenoma in the absence of renal damage, operates to suppress renal renin release and so prevents the initiation of the vicious cycle characteristic of malignant hypertensive vascular disease.
This information has already led to practical gains. In the evaluation of a hypertensive patient with evidence of hyperaldosteronism, it is possible to decide whether the oversecretion is of renal or of adrenocortical origin. Thus, a suppressed plasma renin points to primary adrenal disease and an increased plasma renin suggests renal disease as a prior mechanisms. 3 6 The question remains open whether or not more subtle abnormalities in the renin-angiotensin-aldosterone concatenation might be critically involved in the pathogenesis of the more common hypertensive disorders. More specifically, to what extent is it involved in the large category of patients with "benign" essential hypertension?
To get at this question. ideally, plasma renin activity, circulating angiotensin II, and plasma aldosterone concentrations should be measured simultaneously in these patients. However, only recently have methods been developed that can meet this requirement. In addition, dynamic analysis of the behavior of this hormonal system requires evaluation or control of electrolyte balance, to which the hormones of this system are sharply reactive.6' 7 Utilizing these methods and conditions in our studies of "essential" hypertensive patients, we have already recognized the occurrence of eight out of nine theoretically possible hormonal pattems involving renal renin secretion, angiotensin formation, and aldosterone secretion.8 In our approach the patients are first divided into three groups and then subdivided as follows:
Group I-Low-renin hypertensive patients, who can have one of three associated pattems of aldosterone secretion: low, normal, or high aldosterone.
Group II-Hypertensive patients with normnal plasma renin activity. There are three subeategories of these patients: those who exhibit low, normal, or elevated aldosterone secretion.
Group II-High-renin "essential" hypertensive patients, in whom two subeategories have been identified: those with either a normal or an increased aldosterone secretion.
From the standpoint of defining causal factors in this large population of essential hypertensive patients, such a componenthormonal analysis of the observed abnormalities in the renin-angiotensin-aldosterone system promises to provide a more objective measure of renal or adrenal-cortical participation.
In studies to date, about 50% of patients in the essential hypertensive population, are seemingly entirely normal in renal-endocrine function and adrenal-cortical activity. For this group of patients a more comprehensive study utilizing techniques to assess endocrine reserve such as the manipulation of electrolyte metabolism is still needed. Measurements of other components of the system such as the renin substrate and converting enzyme activity may also be required before it can be established with certainty that the hormonal complex is not abnormal.
The remaining 50% of patients presenting with essential hypertension have been found to exhibit abnormalities in the renin-angiotensin-aldosterone system, which permit their initial classification into seven out of the eight remaining possible abnormal categories defined above. A preliminary report of these provocative new findings has been presented at the 1971 Annual Meeting of the American Heart Association.6 In this study, involving some 219 hypertensive patients, 57% exhibited normal plasma renin activity when measured in relation to. the current state of sodium balance. However, 27% of the patients exhibited subnormal plasma renin levels and another 16% were abnormally high. In all three of these groups of patients the known duration of the hypertension was similar. The degree of diastolic hypertension was similar in the lowrenin and normal-renin groups but it was significantly higher in the high-renin patients.
Of special interest in this study was the finding that the patients with low-renin "essential" hypertension had not yet developed any strokes or myocardial infaretions. In contrast, there was an 11% incidence of these complications in the normal-renin essential hypertensives and a 14% incidence in the highrenin patients. This absence of any demonstrable vascular complication in the low-renin patients appears to have additional significance because the mean age of these patients with low-renin essential hypertension was actually sign-ficantly higher than the mean age Circulation, Volume XLIV, December 1971 of the normal-renin group and similar to the mean age of the high-renin group. Also of interest was the equal frequency of ventricular enlargement in all three groups, probably a reflection of their similar degrees of hypertension.
These findings raise exciting connotations. The data suggest that low-renin essential hypertension is a discrete and fundamentally different hypertensive disorder with a different natural history and a different prognosis. It may be that this type of hypertension is prerenal in origin, the high systemic arterial pressure acting on the afferent arteriolar baroreceptor to suppress renal renin secretion. Whatever the mechanism of the low-renin hypertensive process, the absence of myocardial infarctions and strokes in this particular group certainly suggests the possibility that renin secretion is critically involved in the pathogenesis of vascular complications encountered in the other two groups of hypertensive patients and that the absence of normal amounts of renin in the circulation may operate to protect these patients from serious vascular complications despite a similar degree of hypertension. These new observation may provide an explanation for the striking longevity with absence of complications often observed in individual hypertensive patients known to have had impressive elevations of their blood pressure for up to 30 years. This benign nature of essential hypertension in certain patients has been emphasized in studies of Perera9 and of Pickering.1"
These data provide additional strong evidence for the nonhomogeneity of patients ordinarily classified by usual clinical indices as having "essential" hypertension. Also, from a practical standpoint, this new information may force reappraisal of therapeutic approaches. If it can be substantiated in larger series that low-renin patients have a fundamentally different and more benign disorder then it would follow that the early application of antihypertensive therapy may not be nearly so important in their management. It also follows that treatment should be applied earlier and more diligently in hypertensive patients with elevated plasma renin activity.
Clearly, this group has a poor prognosis. The patients may develop myocardial complications and strokes with greater frequency, and their life expectancy is likely to be shortened. Thus, the measurement of plasma renin in hypertensive patients will provide an additional objective indicator in determining risk and applying treatment.
These results have other and more subtle implications in therapy. It is already known that certain antihypertensive drugs increase plasma renin activity while others can sharply reduce it. It therefore seems possible that in the application of antihypertensive drugs the selection of agents that can correct renin abnormalities may produce a more satisfactory blood-pressure response. Because of this possibility our group has begun a systematic evaluation of changes in blood pressure in relation to changes in renin levels as induced by various antihypertensive drugs. This approach may develop criteria for more rational and more specifically tailored drug therapy.
Altogether, this new information may point the way to an exciting breakthrough in understanding, classification, and treatment of the large population of patients with high blood pressure. Already the results expose a new marker, plasma renin activity, which promises to be a useful determinant of risk of serious cardiac vascular complications as they may occur in the course of hypertensive disease. Whether or not plasma renin measurements can be used to anticipate cardiac or vascular damage in various normotensive patients must also be seriously investigated. Further work is necessary to define and understand the various aldosterone responses in the three different categories of renin secretion and their meaning in pathogenesis.
Studies of other steps in the hormonal system in relation to electrolyte metabolism may also be fruitful. Meanwhile, these results perhaps allow us to understand why certain untreated hypertensive patients can live a long and merry life! JOHN H. LARAGH
